4.2 Article

Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability

Journal

PHARMACOGENETICS AND GENOMICS
Volume 22, Issue 4, Pages 236-246

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e3283500202

Keywords

individualized therapeutics; pediatric rheumatology; pharmacogenomics

Funding

  1. Kansas City Area Life Sciences Award
  2. PhRMA Foundation
  3. Children's Mercy Young Investigator Award
  4. Paul Henson Immunology Research Award
  5. Katharine B. Richardson Grant

Ask authors/readers for more resources

Objective Methotrexate (MTX) has several enzymatic targets in the folate pathway. To better understand the variability in response to MTX, we characterized the interindividual variability of intracellular folate pools in children with juvenile arthritis (JA) and determined clinical and genetic contributors to this variability. Study design This exploratory single-center cross-sectional study evaluated 93 patients with JA not currently receiving MTX. Whole blood, plasma, and erythrocyte folate concentrations were determined after deconjugation and analyzed through reversed-phase separation and stable isotope dilution tandem mass spectrometry. Folate polyglutamates were measured in red blood cell lysates using an ion-pair reversed phase chromatography tandem mass spectrometry method. Results Intracellular concentrations of 5-methyl-tetrahydrofolate (5-CH3-THF) and 5,10-methenyl-tetrahydrofolate varied approximately 20-fold and 80-fold, respectively. The polyglutamated forms of 5-CH3-THF as a percentage of total 5-CH3-THF (5-CH3-THFGlun) were also measured. Hierarchical clustering of 5-CH3-THFGlun revealed two groups, each with two distinct clusters. There was an inverse relationship between 5-CH3-THFGlun chain length and plasma 5-CH3-THF concentrations. A subgroup of patients with a historical intolerance to MTX had significantly lower cellular folate concentrations (P<0.0001). In univariate analyses, clinical variables including sex, age, and folate supplementation in addition to variations in MTHFR, MTR, and SLC25A32 were associated with differential intracellular folate redox concentrations. Multivariate analysis further supported the association of single nucleotide polymorphisms in SLC25A32, MTHFR, and MTR with variability in intracellular 5-CH3-THF and 5,10-methenyl-tetrahydrofolate concentrations, respectively. Conclusion Measurement of intracellular folate isoforms may contribute toward a better understanding of individual MTX effects in JA. Clinical variables in addition to genotypic differences beyond MTHFR may additionally explain differential intracellular folate concentrations and variable responses to MTX. Pharmacogenetics and Genomics 22: 236-246 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

Kristine R. Crews, Andrew A. Monte, Rachel Huddart, Kelly E. Caudle, Evan D. Kharasch, Andrea Gaedigk, Henry M. Dunnenberger, J. Steven Leeder, John T. Callaghan, Caroline Flora Samer, Teri E. Klein, Cyrine E. Haidar, Sara L. Van Driest, Gualberto Ruano, Katrin Sangkuhl, Larisa H. Cavallari, Daniel J. Muller, Cynthia A. Prows, Mohamed Nagy, Andrew A. Somogyi, Todd C. Skaar

Summary: Opioids are commonly used for the treatment of acute and chronic pain, and the clinical effects and adverse events are associated with genes such as CYP2D6, OPRM1, and COMT. While there is extensive research on the association between CYP2D6 and codeine/tramadol, data for hydrocodone, oxycodone, methadone, OPRM1, and COMT are more limited.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Review Pharmacology & Pharmacy

Recent advances in the ontogeny of drug disposition

Brian D. Chapron, Alenka Chapron, J. Steven Leeder

Summary: Developmental changes in childhood impact drug disposition, with advancements in understanding over the past 20 years driven by technological progress in mass spectrometry and in silico tools. However, gaps in research evidence highlight areas where further characterization of developmental trends in drug disposition is needed.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Medicine, Research & Experimental

Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study

Chelsea Hosey-Cojocari, Sherwin S. Chan, Chance S. Friesen, Amie Robinson, Veronica Williams, Erica Swanson, Daniel O'Toole, Jansynn Radford, Neil Mardis, Trevor N. Johnson, J. Steven Leeder, Valentina Shakhnovich

Summary: The liver is the primary organ responsible for clearing most drugs, the clearance capacity is related to organ size and growth in children. Equations relating body surface area and liver volume can adequately estimate liver volumes in children, regardless of weight status.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Article Pharmacology & Pharmacy

Resolving discordant CYP2D6 genotyping results in Thai: platform limitations and novel haplotypes

Yaowaluck Hongkaew, Wendy Y. Wang, Roger Gaedigk, Chonlaphat Sukasem, Andrea Gaedigk

Summary: This study aimed to investigate inconsistent or suspicious CYP2D6 Luminex xTAG genotype calls among Thai subjects, identifying a high number of false genotype calls and revealing three novel haplotypes, two of which are nonfunctional. The findings highlight the importance of systematic characterization of the CYP2D6 locus in diverse populations and rigorous platform validation.

PHARMACOGENOMICS (2021)

Review Pharmacology & Pharmacy

Analysis Approaches to Identify Pharmacogenetic Associations with Pharmacodynamics

Daniel L. Hertz, Laura B. Ramsey, Mathangi Gopalakrishnan, J. Steven Leeder, Sara L. Van Driest

Summary: Pharmacogenetics aims to select the right drug and dose for each patient to optimize therapeutic outcomes, with a focus on pharmacokinetics. Efforts to discover and validate pharmacogenetics-pharmacodynamics associations without the confounding of pharmacokinetic variability could provide valuable insights for future analyses.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Article Pharmacology & Pharmacy

The Impact of Age and Genetics on Naltrexone Biotransformation

Stephani L. Stancil, Whitney Nolte, Robin E. Pearce, Vincent S. Staggs, J. Steven Leeder

Summary: This study aimed to investigate the factors influencing the biotransformation of naltrexone. The results showed that there is significant variability in naltrexone biotransformation in both children and adults, and it is influenced by age, sex, and genetic variation.

DRUG METABOLISM AND DISPOSITION (2022)

Article Pharmacology & Pharmacy

Interindividual Variability and Differential Tissue Abundance of Mitochondrial Amidoxime Reducing Component Enzymes in Humans

Deepak Ahire, Abdul Basit, Lisa J. Christopher, Ramaswamy Iyer, J. Steven Leeder, Bhagwat Prasad

Summary: The mitochondrial amidoxime-reducing component (mARC) enzymes, which metabolize various substances, were quantified in different tissues using targeted proteomics. The abundance of mARC1 and mARC2 in the liver, kidney, intestine, and lung was determined, and their levels were found to be independent of age and sex. These findings provide important information for developing pharmacokinetic models and predicting the metabolism of mARC substrates in vivo.

DRUG METABOLISM AND DISPOSITION (2022)

Article Pharmacology & Pharmacy

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

Xiaoyan Chu, Bhagwat Prasad, Sibylle Neuhoff, Kenta Yoshida, James Steven Leeder, Dwaipayan Mukherjee, Kunal Taskar, Manthena V. S. Varma, Xinyuan Zhang, Xinning Yang, Aleksandra Galetin

Summary: The role of membrane transporters in pharmacokinetics, drug-drug interactions, pharmacodynamics, and drug toxicity is widely recognized. This article highlights recent advances in the study of changes in transporter expression and activity in various diseases and specific populations, with a focus on clinical implications.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Pharmacology & Pharmacy

Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic Acid as a Urinary Biomarker of CYP2D6 Activity

Andrew C. Behrle, Justin Douglas, J. Steven Leeder, Leon van Haandel

Summary: CYP2D6 is an important enzyme involved in the metabolism of clinically used drugs. This study aimed to identify an endogenous urinary biomarker of CYP2D6 activity. The researchers isolated and purified a substance called M1 from urine, and found that it has a similar structure to solanidine, a nitrogen-containing steroidal alkaloid. This discovery may have implications for assessing CYP2D6 activity and guiding treatment with drugs metabolized by this enzyme.

DRUG METABOLISM AND DISPOSITION (2022)

Article Medicine, Research & Experimental

A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence

J. Steven Leeder, Andrea Gaedigk, Krista J. Wright, Vincent S. Staggs, Sarah E. Soden, Yvonne S. Lin, Robin E. Pearce

Summary: This study aimed to investigate the relative contributions of genetic variation, growth, and development on CYP2D6 activity during puberty. Through a three-year longitudinal study on healthy children and adolescents aged 7-15 years, it was found that CYP2D6 genotype was the most important factor contributing to the variability in CYP2D6 activity during puberty, while age and pubertal development had minimal effects. The use of genotype-based dosing guidelines should be considered for CYP2D6 substrates in pediatric patients.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Article Pharmacology & Pharmacy

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity

Pablo Zubiaur, Paula Soria-Chacartegui, Erin C. C. Boone, Bhagwat Prasad, Jean Dinh, Wendy Y. Y. Wang, Santiago Zugbi, Andrea Rodriguez-Lopez, Eva Gonzalez-Iglesias, J. Steven Leeder, Francisco Abad-Santos, Andrea Gaedigk

Summary: A novel haplotype, CYP2C:TG, composed of two non-coding variants, was found to be associated with ultrarapid metabolism of CYP2C19 substrates. However, further analysis revealed that the CYP2C:TG haplotype had no significant effect on the pharmacokinetics of these substrates or the protein abundance and activity of CYP2C8, CYP2C9, CYP2C18, and CYP2C19. On the other hand, CYP2C19 intermediate and poor metabolizers showed distinct differences compared to normal, rapid, and ultrarapid metabolizers. In conclusion, there is insufficient evidence to support the clinical testing of the CYP2C:TG haplotype for drug therapy.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Clinical Neurology

Identifying Effective Treatments for Dystonia in Patients With Cerebral Palsy

Rose Gelineau-Morel, Christopher Smyser, J. Steven Leeder

Summary: The recent focus on improving recognition of dystonia in cerebral palsy (DCP) has highlighted the need for more effective treatments. Current pharmacologic recommendations for DCP are based on anecdotal evidence, with minimal to moderate improvements in dystonia. Precision therapeutics can improve treatment outcomes through predictive biomarker identification, patient stratification, individualized interventions, and monitoring of response.

NEUROLOGY (2023)

Meeting Abstract Pharmacology & Pharmacy

13C-PANTOPRAZOLE BREATH TEST AS A PHENOTYPING PROBE FOR CYP2C19 IN CHILDREN.

K. Feldman, R. Pearce, G. Kearns, J. Leeder, S. Abdel-Rahman, V. Staggs, A. Friesen, A. Gaedigk, J. Weigel, V. Shakhnovich

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Meeting Abstract Pharmacology & Pharmacy

ANTHROPOMETRIC ESTIMATORS OF LIVER VOLUME IN NORMAL-WEIGHT, OVERWEIGHT, AND OBESE CHILDREN.

C. Hosey-Cojocari, S. Chan, C. Friesan, E. Swanson, D. O'Toole, N. Mardis, J. Leeder, V. Shakhnovich

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Meeting Abstract Pharmacology & Pharmacy

INCREASED HEPATIC ADIPOSITY IN THE ABSENCE OF FIBROSIS IS ASSOCIATED WITH DECREASED PANTOPRAZOLE CLEARANCE IN VIVO

V. Shakhnovich, S. Abdel-Rahman, S. Chan, N. Mardis, R. Pearce, V. Williams, C. Friesen, J. Radford, J. Leeder

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

No Data Available